{"filings":[{"id":2078886,"accession_number":"0001116463-26-000048","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-08-05T20:07:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"OraSure Q2 2026 results announced; no financial details available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued a press release on August 5, 2026, for Q2 2026 results.","Press release text was not included in the provided filing excerpt.","No specific financial figures, guidance, or segment data are available from the given text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982996,"accession_number":"0001116463-26-000046","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-06-11T13:02:10+00:00","items":["8.01"],"status":"ready","headline":"OraSure receives FDA clearance for Colli-Pee Dx urine collection kit for STI tests on Roche systems","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clearance covers Colli-Pee Dx kit for use with Roche cobas 5800/6800/8800 systems for CT, NG, TV, MG pathogens.","Kit enables at-home self-collection of first-void urine for both male and female patients.","Subsidiary DNA Genotek's product expands OraSure's at-home diagnostics portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":834679,"accession_number":"0001116463-26-000043","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-06-03T20:32:44+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"OraSure stockholders approve board declassification and 5M share increase in stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 5M share increase to Stock Award Plan; total authorized shares now 6,982,477.","Board declassification approved; transition to annual director elections over three years starting FY2027.","Three Class II directors (Bertrand, Boyd, McMahon) elected with >47M votes each.","Advisory 'say-on-pay' vote passed with ~45M for, ~6M against; Grant Thornton ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91386,"accession_number":"0001116463-26-000037","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q1 2026 results; specific financial figures not disclosed in filing excerpts","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Issued press release with Q1 2026 consolidated financial results.","Held webcast conference call with analysts and investors.","Provided investor presentation (Exhibit 99.2) with business developments.","Specific EPS, revenue, and guidance figures are not available in the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":27925000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91385,"accession_number":"0001193125-26-160336","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"OraSure appoints John D. Bertrand to board, enters cooperation with Altai Capital, seeks declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John D. Bertrand appointed as independent Class II director effective April 16, 2026; term expires at 2026 annual meeting.","Altai Capital withdraws its director nominations and stockholder proposal under the Cooperation Agreement.","Board to propose amendment to declassify the board at 2026 annual meeting, phasing in annual elections.","Altai agrees to standstill and voting provisions; Bertrand joins Nominating and Corporate Governance Committee.","Bertrand co-founded Digital Diagnostics; brings AI/diagnostics experience to OraSure's transformation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101434,"accession_number":"0001193125-26-131979","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OraSure responds to Altai Capital, citing 40% TSR outperformance under CEO; $199M cash; product catalysts ahead","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).","Cash balance of $199M, no debt; $40M share repurchase program initiated in 2025 at avg price $2.85.","Gross margin improved 260bps over 3 years to 43%; SG&A reduced 37% to $73.8M; workforce cut ~40%.","Near-term catalysts: Colli-Pe urine collection device (~$0.5B TAM) and Sherlock CT/NG self-test (~$1.5B TAM).","Expects operating cash flow breakeven entering 2027; new products launching in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101433,"accession_number":"0001116463-26-000011","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David J. Shulkin resigns from OraSure board effective March 2, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Shulkin, M.D. resigned as director and from Compensation Committee, effective March 2, 2026.","Resignation is not due to any dispute with the Company, Board, or management.","Board expressed gratitude for Dr. Shulkin's service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101432,"accession_number":"0001116463-26-000009","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q4/FY2025 results; exhibit details not provided here","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release and investor presentation furnished on Feb 25, 2026 for Q4 and full year ended Dec 31, 2025.","No specific financial figures available in this filing excerpt; actual results are in Exhibits 99.1 and 99.2.","Company held a webcast with CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussing results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":115021000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101431,"accession_number":"0001116463-26-000002","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.","Rapid CT/NG self-test is designed to deliver results in approximately 30 minutes in a disposable, over-the-counter format.","Colli-Pee device is intended for at-home urine collection, including for multiple STI indications.","No timeline for FDA clearance; approval would open new OTC market for OraSure in sexual health diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117802,"accession_number":"0001116463-25-000057","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OraSure CEO and CFO adopt 10b5-1 plans to purchase up to $165K each in common stock","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Carrie Eglinton Manner adopted a plan to buy up to $165,000 of OSUR shares over six months.","CFO Kenneth McGrath adopted a similar plan for up to $165,000 of OSUR shares over six months.","Trading under each plan begins after a cooling-off period of the later of 90 days from adoption or two business days after the 10-K filing, up to 120 days.","Both plans include required good faith certifications; officers have no discretion over transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117801,"accession_number":"0001116463-25-000053","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Technologies Q3 2025 results announced; financial details not provided in filing exhibits","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company reported Q3 2025 consolidated financial results on November 5, 2025.","Specific revenue, EPS, and segment data are not available from the furnished exhibits.","Webcast held with CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath.","Investor presentation available on company website.","No guidance or material business developments disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":88258000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117800,"accession_number":"0001116463-25-000049","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure board chair Aspinall resigns; Boyd appointed director, Kenny named chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mara G. Aspinall resigned from the board and as chair effective Oct 28, 2025; no dispute cited.","John P. Kenny, existing board member, appointed as chair effective same date.","Steven Boyd appointed as Class II director; term expires at 2026 annual meeting.","Boyd joins Audit and Nominating & Governance committees; initial equity grant of $100K in restricted stock vesting over 2 years.","Boyd determined to be independent under Nasdaq rules and Rule 10A-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134245,"accession_number":"0001628280-25-037806","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Technologies reports Q2 2025 earnings; specific financial results not provided in extracted text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release for Q2 2025 consolidated financial results on August 5, 2025.","CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussed results and business developments on a webcast.","Detailed financial figures (revenue, EPS, segment data) are not included in the available filing snippet."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":61173000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151025,"accession_number":"0001628280-25-025491","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"OraSure shareholders approve amendment to 2000 Stock Award Plan, increasing authorized shares by 6M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to Stock Award Plan to increase shares authorized for grant by 6,000,000 shares.","Three Class I directors elected: Carrie Eglinton Manner, John P. Kenny, David J. Shulkin, M.D., each with >54M votes for.","Ratification of Grant Thornton LLP as independent auditor for FY2025 passed with ~65M votes for.","Advisory vote on executive compensation approved with ~52M votes for.","At record date, 77,488,414 shares outstanding; broker non-votes on director elections were 7,988,307."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151024,"accession_number":"0001116463-25-000041","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure Chief Product Officer Kathleen Weber resigns, effective June 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen G. Weber notified resignation as Chief Product Officer on May 8, 2025.","Resignation effective June 30, 2025; treated as 'Good Reason' under Employment Agreement.","Weber eligible for severance benefits contingent on executing a general release of claims.","Employment Agreement and amendments previously filed in 2024 Annual Report on Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151022,"accession_number":"0001116463-25-000043","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K/A","filed_at":"2025-05-09T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Pro forma combined net loss $49.1M, diluted EPS ($0.66) for 2024 after Sherlock acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 19, 2024; consideration includes $5M upfront, up to $20M milestones, and royalties.","Pro forma combined net loss $49.1M vs OraSure standalone net loss $19.5M for year ended Dec 31, 2024.","Pro forma diluted EPS ($0.66) vs standalone ($0.26) on 74.4M shares.","$17M in-process R&D intangible asset recognized for CT/NG test; goodwill $2.5M.","Contingent consideration fair value estimated at $22.9M ($15.9M milestone + royalties)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151023,"accession_number":"0001116463-25-000037","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q1 2025 financial results; specific figures not available in filing attachment","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated May 7, 2025 reports Q1 2025 consolidated financial results.","Management webcast held on same day; CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussed results and business developments.","No earnings per share, revenue, or guidance data included in the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":29931000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169919,"accession_number":"0001116463-25-000013","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OraSure announces $40M stock repurchase program, terminates 2008 plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $40M in common stock repurchases over two years on March 21, 2025.","Prior repurchase program from August 2008 has been terminated.","Repurchases may be through open market, privately-negotiated transactions, or Rule 10b5-1 plan.","Company retains discretion; no obligation to repurchase any specific amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169917,"accession_number":"0001116463-25-000008","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K/A","filed_at":"2025-03-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.","Accumulated deficit reached $149.7M as of Sep 30, 2024; total liabilities $55.3M exceed assets $31.1M.","Cash and cash equivalents $3.8M at Sep 30, 2024; convertible notes of $27.9M outstanding.","Revenue from grants only $1.1M in 9 months 2024, $0.9M in FY2023; no product revenue.","Going concern uncertainty noted, but expected to be resolved by OraSure acquisition in Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169918,"accession_number":"0001116463-25-000002","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q4 2024 financial results: net income $3.2M, EPS $0.26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net income attributable to OraSure was $3.2 million ($0.26 per share), compared to $0.27 per share in Q4 2023.","Q4 2024 net income from continuing operations was $3.2 million ($0.26 per share), compared to $0.24 per share in the prior-year period.","Non-GAAP operating profit for Q4 2024 was $5.3 million, excluding $93,000 in amortization of intangibles and $0.4 million in stock option expenses.","Results were announced via press release and webcast on February 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":185827000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186966,"accession_number":"0001193125-24-285106","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"OraSure acquires Sherlock Biosciences for $5M upfront plus up to $20M milestones and royalties on CT/NG test","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.","Two milestone payments up to $20M aggregate tied to regulatory approval of Sherlock's CT/NG test.","Quarterly mid-single-digit royalties on CT/NG test net sales through 2034.","Sherlock becomes wholly owned subsidiary; convertible notes, preferred, and common stock receive allocated consideration.","Stock options terminated without payment; financial statements to be filed by amendment within 71 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186965,"accession_number":"0001116463-24-000051","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OraSure acquires Sherlock Biosciences; deal terms not disclosed in 8-K filing","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["OraSure announced acquisition of Sherlock Biosciences on December 19, 2024, but no deal value or financial terms provided.","The 8-K furnishes an investor presentation (Exhibit 99.1) with only a title slide; no new substantive details were given.","Acquisition press release referenced as Exhibit 99.2 but full text not included in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186964,"accession_number":"0001116463-24-000048","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Technologies reports Q3 2024 results; details not in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release and conference call held November 6, 2024 for Q3 2024 results.","Management discussed financial results and business developments; no specific figures available here.","CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath participated in the call."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":148382000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203507,"accession_number":"0001116463-24-000042","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure expands board to 7 members, appoints John P. Kenny as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 directors; John P. Kenny appointed as Class I director, effective Sept 6.","Kenny is independent under Nasdaq rules; will serve on Nominating and Corporate Governance Committee.","Initial equity award of $100,000 in restricted shares, vesting over two years, with pro-rata and change-of-control acceleration.","Term expires at 2025 Annual Stockholders Meeting; Kenny has no familial relationship with any director or officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203506,"accession_number":"0001116463-24-000034","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q2 2024 earnings; no figures in filing body","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued August 6, 2024, covering Q2 2024 results and business developments.","Conference call held same day with CEO and CFO discussing results.","Exhibit 99.1 (press release) not included in provided filing text; no specific numbers available."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":108467000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219951,"accession_number":"0001628280-24-024025","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2000 Stock Award Plan to increase authorized shares by 3,000,000; total now up to 5,302,283 shares.","Certificate of Incorporation amended to limit liability of certain officers as permitted by Delaware law; effective May 16, 2024.","Class III directors Nancy J. Gagliano and Lelio Marmora elected with ~57.2M and ~57.3M votes for, respectively.","Grant Thornton LLP ratified as independent auditor for FY2024 with 64.9M votes for; advisory say-on-pay approved with 57.5M for.","All proposals passed; no adjournment motion needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219950,"accession_number":"0001628280-24-021671","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q1 2024 results; specific figures not disclosed in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued May 8, 2024 covering Q1 2024 financial results.","Company held a conference call with analysts to discuss results.","No specific financial numbers are available from the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":54132000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219949,"accession_number":"0001193125-24-094797","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["1.05","7.01","9.01"],"status":"ready","headline":"OraSure reports cybersecurity incident with data exfiltration; Q1 revenue guidance reaffirmed","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Unauthorized third party gained access to certain information systems on or about March 27, 2024.","Company initiated response with cybersecurity experts, notified law enforcement; believes incident contained.","Certain files exfiltrated; investigating extent of sensitive or personal information involved.","Incident has not materially impacted operations, financial systems, or financial condition as of filing date.","Company reiterates previously communicated Q1 2024 revenue guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239697,"accession_number":"0001116463-24-000007","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q4/FY2023 results; press release not provided for review","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on Feb 27, 2024 announcing consolidated financial results for Q4 and FY2023.","Press release (Exhibit 99.1) referenced but not included in the submitted text.","No specific financial figures or business developments available for summary.","Item 7.01 also furnished for conference call remarks; no details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":405472000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239696,"accession_number":"0001116463-24-000003","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OraSure invests in KKR Sapphiros, enters wide-ranging distribution deal","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["OraSure announces investment in KKR Sapphiros, L.P. and a multi-faceted distribution relationship.","No financial terms (investment amount, valuation) disclosed in the 8-K or exhibits provided.","Investor presentation attached as Exhibit 99.1 but not summarized; press release details not included.","Forward-looking statements cite risks: regulatory approvals, supply chain, customer concentration, competition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257205,"accession_number":"0001116463-23-000028","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"OraSure replaces KPMG with Grant Thornton as auditor; discloses material weakness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KPMG dismissed after 2023 audit completion; Grant Thornton appointed for FY2024, effective upon dismissal.","No disagreements with KPMG on accounting principles; only reportable event is a material weakness in customer pricing/internal control over revenue recognition.","Material weakness identified in Q3 2023; financial statements for nine months ended Sept 30, 2023 not misstated.","KPMG authorized to respond to Grant Thornton inquiries regarding the material weakness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257204,"accession_number":"0001116463-23-000022","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q3 2023 results; specific figures not provided in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press released November 7, 2023, covering Q3 2023 consolidated financial results and business updates.","Webcast held with CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussing results.","No revenue, EPS, or segment data available in this excerpt; full exhibit text not included."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":329591000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274556,"accession_number":"0001116463-23-000007","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Q2 2023 earnings announced but no financial details in filing text provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated August 3, 2023, issued but not included in the submitted text.","Webcast conference call held with management discussing results.","Specific revenue, EPS, and segment data are unavailable from the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":240404000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274554,"accession_number":"0001116463-23-000004","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K/A","filed_at":"2023-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OraSure board sets annual say-on-pay votes through 2029 after shareholder advisory vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board determined on Aug 1, 2023 to hold annual say-on-pay votes after 55.8M shares (93.7%) favored one-year frequency.","Votes at May 2023 meeting: 55,752,085 for 1 year, 65,308 for 2 years, 3,632,289 for 3 years, 42,067 abstain.","Next advisory vote on frequency expected at 2029 annual meeting; board will follow shareholder preference for annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274555,"accession_number":"0001116463-23-000002","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure expands board to seven, appoints Robert W. McMahon as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 6 to 7, effective July 31, 2023.","Robert W. McMahon appointed as Class II director with term expiring at 2026 Annual Meeting.","McMahon will serve on Audit Committee and is independent under Nasdaq rules.","He receives initial equity award of $105,000 in restricted shares vesting in two years.","Eligible for cash fees and annual equity per Non-Employee Director Compensation Policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291836,"accession_number":"0000950170-23-022540","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"OraSure shareholders approve 3M share increase to Stock Award Plan; annual meeting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended 2000 Stock Award Plan, adding 3,000,000 authorized shares.","Director Mara G. Aspinall elected for three-year term with 54.4M votes for, 5.1M against.","Say-on-pay passed with 39.4M for, 20.0M against; frequency vote favored every year (55.8M).","Stockholder proposal on greenhouse gas reduction targets defeated with only 4.4M for, 54.6M against.","KPMG ratified as auditor for FY2023 with 64.6M votes for, 1.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291835,"accession_number":"0000950170-23-021806","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"OraSure amends bylaws to align with SEC universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended effective May 9, 2023 to incorporate SEC universal proxy rule requirements.","Stockholder nominations must include intent to solicit proxies from at least 67% voting power.","Company may disqualify nomination if stockholder fails to comply with Rule 14a-19.","Stockholders must certify compliance and notify company if no longer planning to solicit proxies.","Proxy card color reserved for board (white) and must use other color."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291834,"accession_number":"0000950170-23-020635","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Q1 record revenue $155M, GAAP EPS $0.37; guides Q2 rev $62-67M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $155.0M (+129% YoY); InteliSwab revenue $118.3M (+33% sequential).","GAAP EPS $0.37, non-GAAP EPS $0.47; cash and short-term investments $112.4M.","Core business (ex-COVID) revenue $36.6M flat YoY; signed three new molecular partnerships.","2Q23 guidance: total revenue $62-67M, InteliSwab $25-30M; cost savings beyond $15M targeted.","Gross margin 42.5% GAAP, up 200bps sequential; packaging changes expected to save ~$0.50/test."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":154963000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312603,"accession_number":"0000950170-23-008287","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure SVP of Corporate Communications and IR Scott Gleason resigns effective May 26, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Gleason notified resignation on March 15, 2023; effective May 26, 2023.","Gleason served as Senior Vice President of Corporate Communications and Investor Relations.","Resignation is to pursue another opportunity; no replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312602,"accession_number":"0000950170-23-002800","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).","GAAP EPS $0.21, non-GAAP EPS $0.36; full-year GAAP EPS ($0.25), non-GAAP $0.34.","Restructuring combines Molecular & Diagnostics units; 11% non-production role cuts, $15M annual savings by June 2023.","Cash $110.8M, up $9M QoQ; guides Q1 revenue $125–130M (85–92% YoY growth).","New federal InteliSwab contracts through Nov 2023; deal with Quest for saliva collection kits."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":387479000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331114,"accession_number":"0001193125-22-291253","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OraSure awarded DLA contract for up to 36M InteliSwab COVID-19 tests; pricing below prior federal contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Contract from US Defense Logistics Agency for InteliSwab COVID-19 Rapid Test; runs Nov 2022 to Nov 2023.","Estimated 18M tests; maximum award 36M; guaranteed minimum 3.6M tests.","Pricing under this contract is below previously awarded federal contract.","Company not updating Q4 2022 guidance due to lack of order timing visibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331113,"accession_number":"0000950170-22-025070","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"OraSure appoints Kathleen G. Weber Chief Product Officer; Lisa Nibauer resigns as President of Diagnostics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen G. Weber, previously President of Molecular Solutions, appointed as Chief Product Officer effective Nov 14, 2022.","Amendment to employment agreement reflects title/duties change and updates definition of Good Reason; severance unchanged.","Lisa Nibauer resigns as President of Diagnostics effective Nov 11, 2022.","No details on resignation reason or immediate successor for Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331112,"accession_number":"0000950170-22-023216","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure posts record Q3 revenue of $116.5M, up 116% YoY; InteliSwab drives growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $5.3M ($0.07 diluted EPS) vs. loss of $15.0M a year ago; non-GAAP EPS $0.13.","InteliSwab COVID-19 test revenue $79.6M, up 85% sequentially; core diagnostics revenue +14% YoY.","Q3 operating cash flow $16.3M positive vs. ($19.1M) in 2021; cash balance $101.6M.","Q4 revenue guidance $95-100M (49-57% YoY growth); expects continued positive cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":264401000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348672,"accession_number":"0000950170-22-017127","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OraSure appoints Ken McGrath as CFO; three directors resign as part of strategic transformation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken McGrath named CFO effective Aug 8, 2022; succeeds Scott Gleason, who served as interim CFO since Sep 2021.","$475K base salary, 50% target bonus, 131,883 restricted shares (value $400K) vesting over 3 years.","Directors Michael Celano, Ronny Lancaster, Eamonn Hobbs resign effective Nov 8, 2022; board size reduced from 10 to 7.","Mara Aspinall appointed as new Chairwoman of the Board effective Nov 8, 2022.","McGrath brings over 20 years healthcare finance experience, most recently VP Finance at Quest Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348671,"accession_number":"0000950170-22-016137","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Q2 revenue record $80.2M (+39% YoY) but GAAP EPS ($0.26); InteliSwab sales surge 95% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $18.8M vs. $1.4M loss in Q2 2021; gross margin fell to 34.4% from 53.2%.","Non-GAAP gross margin improved 250 bps sequentially to 40.1%; non-GAAP EPS ($0.00).","Q3 revenue guidance $90-95M (67-76% YoY growth); expects positive cash flow by Q4 2022.","Appointed Ken McGrath as CFO effective Aug 8; three directors resign Nov 8; Mara Aspinall to become Board Chair.","InteliSwab capacity now ~1.6M tests/week, expected to nearly double by early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":147938000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348670,"accession_number":"0000950170-22-012733","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K/A","filed_at":"2022-07-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure President of Molecular Solutions rescinds resignation; board accepts retention","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen G. Weber rescinded her May 23 resignation as President of Molecular Solutions.","Board accepted the rescission on July 15, 2022; Weber will remain in role.","Weber continues under existing employment agreement described in the company's 2022 proxy statement.","Original departure effective August 21, 2022, is now nullified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365422,"accession_number":"0000950170-22-011402","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure General Counsel and CCO to depart June 25 after citing organizational changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Agnieszka M. Gallagher, EVP, General Counsel and Chief Compliance Officer, notified termination with Good Reason on June 3, 2022.","Departure effective June 25, 2022; triggered by company organizational changes.","No successor or interim appointment announced as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365421,"accession_number":"0001193125-22-161124","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OraSure appoints Carrie Eglinton Manner CEO effective June 4; ends strategic alternatives review","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carrie Eglinton Manner appointed President and CEO, effective June 4, 2022; replaces interim CEO Nancy Gagliano.","Base salary $700k, target bonus 100% of base; equity awards: $4M RSU (2-year vest), $1.6M RSU (3-year vest), $1.6M performance RSU.","Board concludes strategic alternatives review; will proceed under new CEO, citing market conditions and belief in operational success.","Kathleen Weber, President of Molecular Solutions, resigns effective August 21, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365420,"accession_number":"0000950170-22-010283","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"OraSure shareholders approve 1.5M share increase in stock award plan; reelect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amended stock award plan, increasing authorized shares by 1,500,000 to 3,621,685.","Elected two Class I directors: Eamonn P. Hobbs and David J. Shulkin, M.D., each receiving over 55 million votes.","Ratified KPMG LLP as independent registered public accounting firm for fiscal year 2022 with 60,240,260 votes for.","Approved advisory (non-binding) resolution on executive compensation with 56,687,157 votes for.","All four proposals passed with substantial shareholder support; total outstanding shares as of record date: 73,916,495."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365419,"accession_number":"0000950170-22-009046","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Q1 record revenue $67.7M (+16% YoY) but net loss $20M, InteliSwab scales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.0M ($0.28 diluted EPS) vs net income of $3.8M ($0.05) in Q1 2021; operating loss $16.0M.","Record revenue $67.7M (+16% YoY); non-COVID revenue up 21%; InteliSwab revenue $22.1M (50% sequential growth).","Gross margin fell to 36% from 65% due to InteliSwab scrap, under-absorption, product mix, and subsidy expiration.","Cash from ops used $35.8M; cash and investments $112.2M; $16.9M committed for DoD capacity expansion to be reimbursed.","Strategic alternatives review ongoing; CEO search underway with interim CEO Nancy Gagliano not a candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":67707000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-10T23:59:59+00:00|365419"}